OKYO Pharma
  • Home
  • About
    • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Focus
    • Neuropathic Corneal Pain
    • Rare Corneal Disease
    • NCP Expanded Access
  • Urcosimod
    • Mechanism of Action
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Investors
    • Share Information
    • Shareholder Services
    • Investor Presentation
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
    • FAQs
  • News & Presentations
    • Press releases
    • Presentations & Publications
  • Contact
  • Linkedin
  • Twitter
Select Page
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

by Paul | 30th October 2024 | News

London and New York, NY, October 30, 2024. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy,...

Recent Posts

  • OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
  • OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May
  • OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
  • OKYO Pharma Announces Chairman and Founder Acquires Shares
  • OKYO Pharma Announces Director Acquires Shares

Recent Comments

No comments to show.
OKYO PHARMA

Explore

  • About
  • Disease Focus
  • Urcosimod
  • Pipeline
  • Investors
  • News
  • Contact

Legal

  • Legal
  • Privacy Policy

Follow

  • Follow
  • Follow

© OKYO Pharma, Limited | 2023